La maladie de Parkinson en France (serveur d'exploration) - Corpus (PubMed)

Index « MedMesh.i » - entrée « Placebos »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
Placebo Effect < Placebos < Plant Extracts  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 8.
Ident.Authors (with country if any)Title
000838 (2012) Olivier Rascol ; Joaquim Ferreira ; Laurence Nègre-Pages ; Santiago Perez-Lloret ; Lucette Lacomblez ; Monique Galitzky ; Jean-Christophe Lemarié ; Jean-Christophe Corvol ; Jonathan M. Brotchie ; Laura BossiA proof-of-concept, randomized, placebo-controlled, multiple cross-overs (n-of-1) study of naftazone in Parkinson's disease.
000C93 (2008) Olivier Rascol ; Werner Poewe ; Andrew Lees ; Marina Aristin ; Laurence Salin ; Nolwenn Juhel ; Lisa Waldhauser ; Thomas SchindlerTesofensine (NS 2330), a monoamine reuptake inhibitor, in patients with advanced Parkinson disease and motor fluctuations: the ADVANS Study.
000C98 (2008) David Devos ; Kathy Dujardin ; Isabelle Poirot ; Caroline Moreau ; Olivier Cottencin ; Pierre Thomas ; Alain Destée ; Regis Bordet ; Luc DefebvreComparison of desipramine and citalopram treatments for depression in Parkinson's disease: a double-blind, randomized, placebo-controlled study.
001146 (2003) N V Fedorova[Use of pronoran (piribedil) in Parkinson's disease: the results of a multicenter study].
001627 (1995) P. Limousin ; P. Pollak ; J P Pfefen ; C L Tournier-Gervason ; R. Dubuis ; J E PerretAcute administration of levodopa-benserazide and tolcapone, a COMT inhibitor, Parkinson's disease.
001741 (1993) J M Senard ; O. Rascol ; A. Rascol ; J L MontastrucLack of yohimbine effect on ambulatory blood pressure recording: a double-blind cross-over trial in parkinsonians with orthostatic hypotension.
001862 (1988) O. Rascol ; J L Montastruc ; J M Senard ; J F Demonet ; M. Simonetta ; A. RascolTwo weeks of treatment with deprenyl (selegiline) does not prolong L-dopa effect in parkinsonian patients: a double-blind cross-over placebo-controlled trial.
001875 (1987) M. Ziegler ; V. Fournier ; N. Bathien ; P L Morselli ; P. RondotTherapeutic response to progabide in neuroleptic- and L-dopa-induced dyskinesias.

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Corpus
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/MedMesh.i -k "Placebos" 
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/MedMesh.i  \
                -Sk "Placebos" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    ParkinsonFranceV1
   |flux=    PubMed
   |étape=   Corpus
   |type=    indexItem
   |index=    MedMesh.i
   |clé=    Placebos
}}

Wicri

This area was generated with Dilib version V0.6.29.
Data generation: Wed May 17 19:46:39 2017. Site generation: Mon Mar 4 15:48:15 2024